Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335153 | 0.76 | GAA (0.79) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6413435 | 0.75 | GAA (0.52) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2332683 | 0.75 | CYP3A4 (0.76) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6413117 | 0.73 | CYP2C9 (0.51) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2337751 | 0.73 | GAA (0.74) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2340254 | 0.72 | CYP3A4 (0.69) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2334861 | 0.70 | CYP3A4 (0.68) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6410201 | 0.69 | GAA (0.52) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6411956 | 0.68 | KMT2A (0.69) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2339213 | 0.68 | CYP3A4 (0.64) | CYP3A4CYP2C9KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-04 | — | — | US | claimed |
| WO-2012000036-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-05 | — | — | WO | claimed |
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-04 | — | — | US | disclosed |
| WO-2012000036-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | FBP1, G6PC1, G6PD | CYP3A4 1707/4885CYP2C9 4300/4885KMT2A 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.